Lista de obras - alessandro maria vannucchi

A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: morphological and molecular characteristics of a highly aggressive disease

scientific article published on 03 April 2020

A life-threatening ruxolitinib discontinuation syndrome

artículo científico publicado en 2017

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

artículo científico publicado en 2014

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

artículo científico publicado en 2015

BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma

artículo científico publicado en 2021

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

artículo científico publicado en 2020

Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms

scientific article published on 12 November 2019

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients

scientific article published on 13 December 2019

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

artículo científico publicado en 2017

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

artículo científico publicado en 2020

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis

artículo científico publicado en 2022

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

artículo científico publicado en 2017

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

artículo científico publicado en 2017

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

scientific article published on 07 January 2021

How I treat polycythemia vera.

artículo científico publicado en 2014

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

artículo científico publicado en 2020

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data

artículo científico publicado en 2020

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

artículo científico publicado en 2019

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

artículo científico publicado en 2019

JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease

artículo científico publicado en 2017

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis

scientific article published on 11 July 2016

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

artículo científico publicado en 2018

Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis

artículo científico publicado en 2019

Pegasus causes inherited thrombocytopenia

scientific article published on 01 December 2019

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

artículo científico publicado en 2018

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

artículo científico publicado en 2017

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

artículo científico publicado en 2007

Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis

artículo científico publicado en 2018

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis

artículo científico publicado en 2017

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

artículo científico publicado en 2017

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

scientific article published on 29 May 2019

Second cancers in MPN: Survival analysis from an international study

artículo científico publicado en 2019

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

scientific article published on 10 May 2019

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

artículo científico publicado en 2019

The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19

artículo científico publicado en 2020

The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all

scientific article published on 18 December 2018

Traffic lights for ruxolitinib.

artículo científico publicado en 2017

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

artículo científico publicado en 2020

Validation of the Mayo alliance prognostic system for mastocytosis

artículo científico publicado en 2019

Lista de obras de alessandro maria vannucchi

A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: morphological and molecular characteristics of a highly aggressive disease

A life-threatening ruxolitinib discontinuation syndrome

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms

Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients

Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis

Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients.

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

How I treat polycythemia vera.

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data

Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative

JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea

Myelodysplasia as assessed by multiparameter flow cytometry refines prognostic stratification provided by genotypic risk in systemic mastocytosis

Pegasus causes inherited thrombocytopenia

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear

Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Second cancers in MPN: Survival analysis from an international study

Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19

The JAK2 46/1 (GGCC) MPN-predisposing haplotype: A risky haplotype, after all

Traffic lights for ruxolitinib.

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis

Validation of the Mayo alliance prognostic system for mastocytosis